Kalydeco has been approved by the Food And Drug Administration (FDA) to treat a vicious type of Cystic Fibrosis (CF). CF is a deadly recessive disease which targets the lungs, but can also harm the liver, pancreas, and intestine. It occurs from the unusual transport of chloride and sodium across the epithelium, causing mucus buildup in the lungs, and thick secretions…

The lung clearance index (LCI) is a sensitive non-invasive marker of early lung disease in young children with cystic fibrosis (CF), according to a new study from Australian researchers…

According to a new Australian study published online before he print publication in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, the lung clearance index (LCI) is a sensitive, non-invasive marker of early lung disease in young children with cystic fibrosis (CF)…

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

A new study found that the combination of inhaled dry powder mannitol with standard therapy for cystic fibrosis resulted in maintained improvement in lung function for 12 months. In addition to being effective and safe, the easy administration of the treatment might help enhance adherence with treatment in individuals suffering with the condition…

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

Results of the pivotal Phase 3 clinical trial published in the Nov. 3, 2011 New England Journal of Medicine, find that the oral medication ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other signs and symptoms for cystic fibrosis (CF) patients…

A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, “A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation,” led by Bonnie W…

A new discovery by Californian scientists may lead to a pharmaceutical breakthrough for a wide range of illnesses that involve the hydration of cells that line the inner surfaces of our body’s organs and tissues…

New research in The FASEB Journal suggests that cigarette smoke interferes with the Cystic Fibrosis Transmembrane Conductance Regulator protein, leading to dry, sticky mucus and increased infections. If you smoke cigarettes, you have more in common with someone who has cystic fibrosis than you think…

Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator (CFTR)…

When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals…

Researchers have identified an unconventional path that may correct the defect underlying cystic fibrosis, according to a report in the September 2nd issue of the journal Cell, a Cell Press publication. This new treatment dramatically extends the lives of mice carrying the disease-associated mutation…

A study published on bmj.com indicates, that even though improvements have been made in the last half century for the survival of cystic fibrosis sufferers, females and individuals from socio-economically disadvantaged backgrounds continue to die younger than males and those more privileged in society…

Azithromycin is an antibiotic that also has antiinflammatory properties. It is these antiinflammatory properties that are thought to account for the improvement in clinical outcome observed when patients with chronic lung diseases such as cystic fibrosis are treated long-term with azithromycin…

Case Western Reserve University School of Medicine has received a $2.1 million grant from the National Center for Research Resources, part of the National Institutes of Health (NIH), to expand basic research models for the study of cystic fibrosis (CF). CF is an inherited disease that causes thick, sticky mucus to build up in the lungs and digestive tract…

A comparative study published in July 13 issue of JAMA noticed, treatment based on a new invasive diagnostic procedure for treating cystic fibrosis in infants that involves obtaining and culturing fluid samples from the lungs, when compared with standard diagnostic procedure, did not have a lower prevalence of lung-damaging infection or structural lung injury at 5 years of age…

Astra Biotech GmbH is in the pre-launch phase of its newly developed test, based on microarray technology, for rapid simultaneous detection of 25 of the most common mutations causing cystic fibrosis in pan-European populations. This initiative supports Astra Biotech’s aim of facilitating early diagnosis of individuals’ risk factors through innovative assays…

PTC Therapeutics, Inc. (PTC) announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal…

An international research team led by Queen’s University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the ‘Celtic Gene’, a genetic mutation which is particularly common in Ireland…

An international research team led by Queen’s University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the ‘Celtic Gene’, a genetic mutation which is particularly common in Ireland…

Glasgow biopharmaceutical firm, Lamellar Biomedical Ltd, launched four years ago to develop a new class of therapies for the prevention, treatment and control of severe respiratory disease, today announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has received Orphan Drug Designation from the European Commission…

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE

Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA)…

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF). STRIVE was designed to evaluate VX-770 among 161 people 12 years or older with a mutation known as G551D in the CF gene…

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis. The study enrolled 62 people with two copies of the most common CF mutation, known as Delta F508. The trial lasted three weeks…

A team of international researchers, including Case Western Reserve University School of Medicine, have discovered regions of the genome that affect the severity of the genetic disease cystic fibrosis (CF), the most common lethal genetic disease affecting children in North America…

A team of researchers, including a number from the University of North Carolina at Chapel Hill School of Medicine, have pinpointed regions of the genome that contribute to the debilitating lung disease that is the hallmark of cystic fibrosis. Their findings provide insight into the causes of the wide variation in lung disease severity experienced by CF patients…

Johns Hopkins Institute for Genetic Medicine researchers working as part of the North American Cystic Fibrosis Consortium have discovered two regions of the genome that affect the severity of cystic fibrosis, a genetic condition that causes scarring throughout the body, affecting most notably the pancreas and lungs…